Patents by Inventor BinQing Wei

BinQing Wei has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220073520
    Abstract: Cinnoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the cinnoline compounds.
    Type: Application
    Filed: March 26, 2021
    Publication date: March 10, 2022
    Applicant: Genentech, Inc.
    Inventors: Sushant Malhotra, Michael Siu, Weiru Wang, BinQing Wei, Aihe Zhou, Bryan K. Chan, Lewis J. Gazzard, Timothy Heffron, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
  • Patent number: 11242344
    Abstract: The present disclosure relates to bifunctional compounds, which can be used as modulators of targeted ubiquitination. In particular, the present disclosure is directed to compounds which contain on one end a VHL ligand moiety, which binds to the VHL E3 ubiquitin ligase, and on the other end a moiety that binds a target protein such that degradation of the target protein/polypeptide is effectuated. Also disclosed are VHL ligands.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: February 8, 2022
    Assignee: Genentech, Inc.
    Inventors: Nicole Blaquiere, Peter Dragovich, Lewis J. Gazzard, Thomas Pillow, Steven T. Staben, Binqing Wei, Jianfeng Xin
  • Publication number: 20210332064
    Abstract: 3-Carbonylaminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylaminoisoquinoline compounds.
    Type: Application
    Filed: April 1, 2021
    Publication date: October 28, 2021
    Applicant: Genentech, Inc.
    Inventors: Jun Liang, Rohan V. Mendonca, Michael Siu, John Tellis, Weiru Wang, BinQing Wei, Bryan Chan, Edna F. Choo, Joy Drobnick, Lewis J. Gazzard, Timothy Heffron
  • Publication number: 20210309660
    Abstract: The present disclosure relates to bifunctional compounds, which can be used as modulators of targeted ubiquitination. In particular, the present disclosure is directed to compounds which contain on one end a VHL ligand moiety, which binds to the VHL E3 ubiquitin ligase, and on the other end a moiety that binds a target protein such that degradation of the target protein/polypeptide is effectuated. Also disclosed are VHL ligands.
    Type: Application
    Filed: April 24, 2020
    Publication date: October 7, 2021
    Inventors: Nicole Blaquiere, Peter Dragovich, Lewis J. Gazzard, Thomas Pillow, Steven T. Staben, Binqing Wei, Jianfeng Xin
  • Publication number: 20210299110
    Abstract: Azaindole compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the azaindole compounds.
    Type: Application
    Filed: February 17, 2021
    Publication date: September 30, 2021
    Applicant: Genentech, Inc.
    Inventors: Timothy HEFFRON, Sushant MALHOTRA, BinQing WEI, Bryan CHAN, Lewis GAZZARD, Emanuela GANCIA, Michael LAINCHBURY, Andrew MADIN, Eileen SEWARD, Yonghan HU
  • Publication number: 20210277024
    Abstract: Naphthyridine compounds of formula (I). variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
    Type: Application
    Filed: January 22, 2021
    Publication date: September 9, 2021
    Applicant: Genentech, Inc.
    Inventors: Terry Kellar, Jun Liang, Sushant Malhotra, Rohan V. Mendonca, Michael Siu, Craig Stivala, John C. Tellis, BinQing Wei, Bryan K. Chan, Lewis J. Gazzard, Timothy Heffron, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
  • Publication number: 20210253580
    Abstract: Isoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
    Type: Application
    Filed: January 22, 2021
    Publication date: August 19, 2021
    Applicant: Genentech, Inc.
    Inventors: Jun Liang, Sushant Malhotra, Rohan V. Mendonca, Naomi Rajapaksa, Michael Siu, Craig Stivala, John C. Tellis, BinQing Wei, Bryan K. Chan, Joy Alison Drobnick, Lewis J. Gazzard, Timothy Heffron, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Mary Seward, Matthew W. Cartwright, Emanuela Gancia, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu
  • Publication number: 20210221821
    Abstract: The present disclosure relates to compounds and salts thereof that are useful for inhibiting target polypeptides and proteins, in particular, bromodomain (e.g., BRD4) proteins. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated diseases or disorders.
    Type: Application
    Filed: March 10, 2021
    Publication date: July 22, 2021
    Applicant: Genentech, Inc.
    Inventors: Robert Anthony BLAKE, Peter DRAGOVICH, Lewis J. GAZZARD, Susan KAUFMAN, Tracy KLEINHEINZ, Thomas PILLOW, Steven T. STABEN, Binqing WEI
  • Patent number: 11034692
    Abstract: Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: June 15, 2021
    Assignee: Genentech, Inc.
    Inventors: Bryan Chan, Blake Daniels, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Malcolm Huestis, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Michael Siu, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Emanuela Gancia, Graham Jones, Michael Lainchbury, Andrew Madin, Eileen Seward, David Favor, Kin Chiu Fong, Andrew Good, Yonghan Hu, Baihua Hu, Aijun Lu
  • Publication number: 20210163417
    Abstract: Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.
    Type: Application
    Filed: July 6, 2020
    Publication date: June 3, 2021
    Applicant: Genentech, Inc.
    Inventors: Bryan Chan, Joy Drobnick, Lewis Gazzard, Timothy Heffron, Jun Liang, Sushant Malhotra, Rohan Mendonca, Naomi Rajapaksa, Craig Stivala, John Tellis, Weiru Wang, BinQing Wei, Aihe Zhou, Matthew W. Cartwright, Michael Lainchbury, Emanuela Gancia, Eileen Seward, Andrew Madin, David Favor, Kin Chiu Fong, Yonghan Hu, Andrew Good
  • Patent number: 10952995
    Abstract: Azaindole compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the azaindole compounds.
    Type: Grant
    Filed: September 12, 2019
    Date of Patent: March 23, 2021
    Assignee: Genentech, Inc.
    Inventors: Timothy Heffron, Sushant Malhotra, BinQing Wei, Bryan Chan, Lewis Gazzard, Emanuela Gancia, Michael Lainchbury, Andrew Madin, Eileen Seward, Yonghan Hu
  • Publication number: 20210079002
    Abstract: Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: August 24, 2020
    Publication date: March 18, 2021
    Applicant: Genentech, Inc.
    Inventors: James John CRAWFORD, Daniel Fred ORTWINE, BinQing WEI, Wendy B. YOUNG
  • Publication number: 20200157240
    Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.
    Type: Application
    Filed: November 26, 2019
    Publication date: May 21, 2020
    Inventors: John FLYGARE, Janet GUNZNER-TOSTE, Thomas PILLOW, Brian SAFINA, Vishal VERMA, Binqing WEI, Guiling ZHAO, Leanna STABEN, Philip Wilson HOWARD, Luke MASTERSON
  • Patent number: 10639373
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
    Type: Grant
    Filed: July 16, 2018
    Date of Patent: May 5, 2020
    Assignee: Genentech, Inc.
    Inventors: Peter Dragovich, Thomas Pillow, Jack Sadowsky, Mark X. Sliwkowski, BinQing Wei
  • Patent number: 10632196
    Abstract: The invention provides antibody-drug conjugates comprising an antibody conjugated to a pyrrolobenzodiazepine drug moiety via a disulfide linker, pyrrolobenzodiazepine linker-drug intermediates, and methods of using the antibody-drug conjugates.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: April 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Peter Dragovich, Thomas Pillow, Jack Sadowsky, Mark X. Sliwkowski, BinQing Wei
  • Patent number: 10632210
    Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
    Type: Grant
    Filed: October 3, 2018
    Date of Patent: April 28, 2020
    Assignee: Genentech, Inc.
    Inventors: Ho Huat Lee, Moana Tercel, John A. Flygare, Janet Gunzner-Toste, Thomas H. Pillow, Brian Safina, Leanna Staben, Vishal Verma, BinQing Wei, Guiling Zhao
  • Publication number: 20200108075
    Abstract: 3-Carbonylamino-8-aminoisoquinoline compounds of formula (I): variations thereof, and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the 3-carbonylamino-8-aminoisoquinoline compounds.
    Type: Application
    Filed: October 3, 2019
    Publication date: April 9, 2020
    Applicant: Genentech, Inc.
    Inventors: Jun LIANG, Rohan V. MENDONCA, Michael SIU, John TELLIS, Weiru WANG, BinQing WEI, Bryan CHAN, Edna F. CHOO, Joy DROBNICK, Lewis J. GAZZARD, Timothy HEFFRON
  • Patent number: 10576164
    Abstract: Conjugate compounds of formula (A): wherein: R2 is where R36a and R36b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester; or, when one of R36a and R36b is H, the other is selected from nitrile and a C1-4 alkyl ester; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, NO2, Me3Sn and halo; R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, NO2, Me3Sn and halo; Y is selected from formulae A1, A2, A3, A4, A5 and A6: L is a linker connected to a cell binding agent; CBA is the cell binding agent; n is an integer selected in the range of 0 to 48; RA4 is a C1-6 alkylene group; either (a) R10 is H, and R11 is OH, ORA, where RA is C1-4 alkyl; or (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is OSOzM, wher
    Type: Grant
    Filed: October 17, 2017
    Date of Patent: March 3, 2020
    Assignees: MedImmune Limited, Genentech, Inc.
    Inventors: Philip Wilson Howard, John A. Flygare, Thomas Pillow, Binqing Wei
  • Publication number: 20200062769
    Abstract: Heteroaryl pyridone and aza-pyridone compounds are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using heteroaryl pyridone and aza-pyridone compounds for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Application
    Filed: October 31, 2019
    Publication date: February 27, 2020
    Applicant: Genentech, Inc.
    Inventors: James John CRAWFORD, Daniel Fred ORTWINE, BinQing WEI, Wendy B. YOUNG
  • Patent number: RE48239
    Abstract: Heteroaryl pyridone and aza-pyridone compounds of Formula I are provided, where one or two of X1, X2, and X3 are N, and including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Type: Grant
    Filed: October 30, 2018
    Date of Patent: October 6, 2020
    Assignee: Genetech, Inc.
    Inventors: James John Crawford, Daniel Fred Ortwine, BinQing Wei, Wendy B. Young